PureTech established the underlying programs and platforms that resulted in 28 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including two taken from inception at PureTech to FDA and EU regulatory clearances and a third that has been filed for FDA approval.
PureTech established the underlying programs and platforms that resulted in 28 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including two taken from inception at PureTech to FDA and EU regulatory clearances a third soon filing for FDA approval.

Wholly Owned Programs1

Conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis
100% Equity
Phase 2b
1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication.

Founded Entities

$3.8B2
Investments and Non-Dilutive Funding Raised by Founded Entities Since July 2018
Central nervous system (CNS) related conditions
100% Equity
Phase 2
Advancing transformative medicines for people living with psychiatric and neurological conditions
2.3% Equity plus Milestone Payments/ 20% Sublicense Revenue/ Royalties & up to $500M from agreement w/Royalty Pharma3
NASDAQ: KRTX
Phase 3
Pioneering a new category of oral therapies based on defined bacterial consortia
41% Equity
Phase 3 Ready
Hematological malignancies, such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and locally advanced/metastatic solid tumors, including head and neck cancers
100% Equity
Phase 1/2
Engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers
4.0% Equity
Phase 1/2a
Engineering hydrogels to enable the oral administration of peptide therapeutics (e.g., GLP-1 agonists)
73.8% Equity
Preclinical
Pioneering the development of cognitive treatments through game-changing technologies
14.6% Equity
Commercial
A voice-based artificial intelligence platform to detect changes in health
35.2% Equity
Commercial Release

Note: PureTech retains control of  Entrega, Inc., and it is consolidated in PureTech’s financial statements. PureTech maintains ownership of equity interests, but does not control, Karuna Therapeutics, Inc., Akili, Inc., Sonde Health, Inc. Vor Biopharma Inc., and Vedanta Biosciences, Inc. Relevant ownership interests for non-public Founded Entities, Vedanta, Sonde and Entrega were calculated on a partially diluted basis (as opposed to a voting basis) as of June 30, 2023, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Karuna, Akili and Vor ownerships were calculated on a beneficial ownership basis in accordance with SEC rules as of February 15, 2024, February 21, 2024 and November 3, 2023, respectively. As of March 1, 2023, the date on which PureTech was deemed to no longer control Vedanta Biosciences, PureTech’s percentage ownership of Vedanta Biosciences was approximately 40.8%. Vedanta’s 2023 $106.5 million financing round was structured as convertible debt. PureTech’s current ownership does not take into account any potential future dilution, if applicable, as a result of conversion of that debt amount. With the exception of Plenity® and EndeavorRx®, candidates are investigational and have not been cleared by the FDA for use in the U.S.
2 Funding figure can include private equity financings, loans and promissory notes, public offerings or grant awards, and gross proceeds from SPAC mergers. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations.
3 As of March 22, 2023, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on net sales up to $2 billion annually, after which threshold PureTech will receive 67% of the royalty payments and Royalty Pharma will receive 33%. PureTech retains its equity ownership in Karuna. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals and 20% of sublicense income.

Consolidated Cash and cash equivalents

Approximately $320M
Consolidated Cash, Cash Equivalents and Short-Term Investments at year end of 20231
Operational Runway into 2027
1The preliminary selected financial results reported by the Company are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results in April 2024.

Developing breakthrough medicines at PureTech